Anna Lee
Yonsei University
6 Papers
13 Citations
Anna Lee is an academic researcher from Yonsei University. The author has contributed to research in topics: Cirrhosis & Antithrombin. The author has an hindex of 2, co-authored 5 publications.
Chat about Author
Papers
Diagnostic efficacy of plasma urokinase-type plasminogen activator and plasminogen activator inhibitor-2 in differentiation of hepatocellular carcinoma from cirrhosis.
TL;DR: The findings raise the question as to whether these markers could be considered as useful screening markers for earlier detection of HCC in liver cirrhosis because discriminant functions of u-PA and PAI-2 were not significant.
7
The relationship between cytokine concentrations and hemostatic abnormalities in patients with liver cirrhosis of postviral or cryptogenic origin
TL;DR: It is concluded that TNF-α could play an important part in the activation of hemostatic mechanism in liver cirrhosis, a condition commonly associated with intravascular coagulation.
3
Quantitative levels of fibrin(ogen) related materials in cerebrospinal fluid in patients with bacterial meningitis and other conditions
TL;DR: The levels of D and E fibrin(ogen) related materials in cerebrospinal fluid were increased to highly significant levels in the bacterial meningitis group including tuberculousMeningitis (mean; D=36.4, E=6.4ng/ml) (p).
2
A case of prenatal diagnosis of hemophilia A.
TL;DR: Recently, the authors have made a prenatal diagnosis of hemophilia A in an obligate carrier with a male fetus at 24 weeks of gestation by pure fetal sampling and accurate factor VIII coagulant assay, which was repeatedly less than 1% at 28 weeks of pregnancy.
A Curious Case of Splenic Leiomyosarcoma of Vascular Origin in a Post–Liver Transplant Recipient
TL;DR: A 66-year-old man with a history of alcohol-related liver cirrhosis who underwent liver transplant 7 years earlier with hepatocellular carcinoma discovered on explant presented with fatigue and weight loss and was switched to an mechanistic target of rapamycin (mTOR) inhibitor after surgery to prevent cancer recurrence.
1